Cancer-associated thrombosis, with the incidence rising over the years, is associated with
significant morbidity and mortality in patients with cancer. Recent advances in the treatment …

Background Venous thromboembolism (VTE) remains the third leading cause of acute
cardiovascular syndrome following myocardial infarction and ischemic stroke. The global …

Introduction Patients with cancer and venous thromboembolism (VTE) show a high risk of
VTE recurrence during anticoagulant treatment. This study aimed to develop a predictive …

Background In the recent years, numerous studies on the optimal treatment and prevention
of cancer-associated venous thromboembolism (VTE) have been published, leading to …

Venous thromboembolism (VTE), which includes pulmonary embolism and deep vein
thrombosis, is a leading cause of morbidity and mortality in patients with cancer. Based on …

Prevention of venous thromboembolism (VTEp) is an integral part in the care of orthopaedic
patients. VTE the leading cause of preventable mortality in hospital and orthopaedic surgery …

The direct anticoagulants (DOACs), apixaban and rivaroxaban, are used for extended-
phase treatment of venous thromboembolism (VTE) and have labeling for dose reduction for …

Cancer-associated thrombosis (CAT) is a devastating complication of cancer that can
significantly impact a patient's health and life. The incidence of CAT is approximately 20 …

Objectives Quantification of direct oral anticoagulant (DOAC) plasma levels can guide
clinical management, but insight into clinical scenarios surrounding DOAC-calibrated anti …

Résumé La thrombose associée au cancer est une complication fréquente résultant de
divers mécanismes vasculaires liés au cancer, au traitement antitumoral et au patient, et qui …